Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondylarthropathy

Arthritis and Rheumatism

Volumn 46, Issue 3, 2002, Pages 755-765

  Van Den Bosch, Filip ^a   Kruithof, Elli ^a   Baeten, Dominique ^a   Herssens, Annemie ^a   De Keyser, Filip ^a   Mielants, Herman ^a   Veys, Eric M ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; PLACEBO; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMMON COLD; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTITIS; DISEASE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPISTAXIS; FATIGUE; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; HYPERVENTILATION; MALE; MILIARY TUBERCULOSIS; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; SPONDYLOARTHROPATHY; TREATMENT OUTCOME; UVEITIS; VERTIGO;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; SAFETY; SPONDYLARTHROPATHIES; TUBERCULOSIS;

EID: 0036188187     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.511     Document Type: Article

References (38)

1. Seronegative polyarthritis: A unified concept
2. Undifferentiated spondyloarthropathies
3. Ileocolonoscopic findings in seronegative spondylarthropathies
4. The evolution of the spondyloarthropathies in relation to gut histology. I. Clinical aspects
5. Long-term evolution of gut inflammation in patients with spondyloarthropathy
6. The evolution of spondyloarthropathies in relation to gut histology. III. Relation between gut and joint
7. Controlled trial of sulfasalazine in the treatment of ulcerative colitis
8. Effect of sulfasalazine in patients with active Crohn's disease: A controlled double-blind study
9. Sulfasalazine in the treatment of spondylarthropathy: A randomized, multicenter, double-blind, placebo-controlled study
10. Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: A Department of Veterans Affairs cooperative study
11. Methotrexate use in psoriasis and psoriatic arthritis
12. Cyclosporine for plaque-type psoriasis: Results of a multidose, double-blind trial
13. Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: A one-year prospective study
14. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody
15. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
16. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease
17. Infliximab for the treatment of fistulas in patients with Crohn's disease
18. Crohn's disease associated with spondyloarthropathy: Effect of TNF-α blockade with infliximab on the articular symptoms
19. Successful treatment of severe psoriatic arthritis with infliximab
20. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomised trial
21. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
22. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis
23. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
24. Effects of a loading dose regimen of 3 infusions of chimeric monoclonal antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: An open pilot study
25. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor α monoclonal antibody infliximab
26. Needle arthroscopy of the knee with synovial biopsy sampling: Technical experience in 150 patients
27. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy
28. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria
29. A new approach to defining disease status in ankylosing spondylitis: The Bath ankylosing spondylitis disease activity index
30. A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath ankylosing spondylitis functional index
31. Evaluation of a functional index and an articular index in ankylosing spondylitis
32. Defining spinal mobility in ankylosing spondylitis (AS): The Bath AS metrology index
33. Severe psoriasis: Oral therapy with a new retinoid
34. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α: Findings in open-label and randomized placebo-controlled trials
35. Etanercept therapy in rheumatoid arthritis: A randomized, controlled trial
36. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
37. Impaired Thl cytokine production in spondyloarthropathy is restored by anti-TNFα
38. Immunomodulatory effects of anti-tumor necrosis factor α therapy on synovium in spondylarthropathy: Histologic findings in eight patients from an open-label pilot study